Dyne Therapeutics Announces FDA Acceptance of BLA for Zeleciment Rostudirsen with Priority Review

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its biologics license application (BLA) for zeleciment rostudirsen (DYNE-251) for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping. The FDA granted the BLA Priority Review.